Cell based assays 2012


Published on

Cell based assays
3d cell culture

Published in: Technology
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Cell based assays 2012

  1. 1. 1 ATTA Cell Based Assays 2012 26th -27th June 2012 London, UK Cell Based Assays Conference is a much awaited symposium where latest developments on cell based assays and their significance to the strategic future of Research and Development in pharmaceutical industry will be discussed and debated. Here in Cell Based Assays Conference keynote speakers like Eberhard Krausz, Marianthi Papakosta, Marie H. Delmotte, Dr. Peter Horvath, Professor Marc Bickle etc will come and provide latest updates on cell based assays. Plenary sessions, debates and discussions will be very much beneficial Who should attend this event? Heads of Department, Directors, Managers, Team Leaders Researchers and Scientists from:  Screening  Pre-clinical Research  Pharmacology  Lead discovery technologies  Molecular and cellular biology  Biological technologies  Lead generation and optimization  High-content analysis  Target identification and validation  Target discovery  In vitro assays  Compound profiling  Assay development1 ATTA
  2. 2. Cell Based Assays 2012 26th-27th June 2012, London UK.Key SpeakersEberhard Krausz, Director, Assay Development & Target Validation, Enabling Biology, JanssenResearch & DevelopmentMarianthi Papakosta Scientific Director at Grunenthal GmbHMarie H. Delmotte Lab Head Cellular and Molecular Biology at NovartisDr. Jeroen van Bergeijk GPRD Research Neuroscience Molecular Biology & Biochemistry AbbottGmbH & Co. KGDr. Xavier Leroy Project Promoter & Leader Associate Director Drug Discovery Dept. ActelionPharmaceuticals LtdThomas Koblizek Senior Scientist R&D LonzaDr. Peter Horvath, Head of image and data analysis, ETH Zurich, Light Microscopy Centre.Marc Bickle Head of Technology Development Studio at Max Planck Institute of Molecular CellBiology and GeneticsRemko de Pril Team Leader Target Discovery and High-Content Screening GalapagosDavid R. Greaves Professor of Inflammation Biology Sir William Dunn School of Pathology Universityof OxfordRobin Ketteler MRC LMCB University College LondonJens Kelm, PhD, co-founder of InSphero AGSponsored by:InSphero AG Lonza TAP BiosystemsOrganized by: ATTA LTD. http://www.attaconference.co.uk
  3. 3. Day 1 Cell Based Assays 2012 12:00 Sponsor Speaking section th June 2012 contact09:00 Registration and refreshments 26 tareef.ahmed@atta-online.co.uk09:30 Opening address from the Chair 12:40 Networking lunch09:40 Quantitative analysis of cell-based 13:40 Targeting endogenous stem cellshigh-content drug and siRNA screens - for therapyHow can machine intelligence help? Targeting endogenous stem cells forImage quality enhancement (vignetting) therapy and related approaches (e.g.Image analysis of end point- and time- IPSCs).resolved data (segmentation, feature Recruitment of (neuronal) stem andextraction, tracking) Multi-parametric precursor cells for regeneration &analysis of single cell-based assays using neuroprotectionmachine learning (classification, Targeting cancer stem cells forregression, method optimization, weakly- oncologysupervised approaches) Hedgehog signalingStatistical analysis and quality control Dr. Jeroen van Bergeijk GPRDissues Research Neuroscience MolecularDr. Peter Horvath, Head of image and Biology & Biochemistry Abbott GmbHdata analysis, ETH Zurich, Light & Co. KGMicroscopy Centre 14:20 Carcinogenicity risk assessment10:20 Systematic analysis of complex of Biologics using in vitro cell-basedsignal transduction pathways using protein assaysfragment complementation assays Marie H. Delmotte Lab Head -Protein:protein interactions Classical Cellular and Molecular Biology atGPCR signaling Non-classical GPCR Novartispathways and interconnectivity Examplesfor complex networks The PCA working 15:00 Afternoon Refreshmentsprinciple Some PCA examplesSomatostatin homodimers/heterodimer 15:20 Sponsor Speaking section contactdata CXCR4 agonist/antagonist data tareef.ahmed@atta-online.co.uk for moreThomas Koblizek Senior Scientist R&D detailLonza 16:00 Pores for thought; analyses of11:00 Morning refreshments TRPV1 chimeras using a bespoke heat activation assay, demonstrate that11:20 Use of cell based GPCR assays to differences in the pore domain conferidentify novel CB2 agonists and species specific pharmacologicalchemokine receptor antagonists sensitivityDavid R. Greaves Professor of Marianthi Papakosta ScientificInflammation Biology Sir William Director at Grunenthal GmbHDunn School of Pathology University ofOxford 16:40 Closing remarks from the Chair
  4. 4. Day 2 Cell Based Assays 2012 th 27 June 201209:00 Registration and refreshments 12:40 Networking lunch09:30 Opening address from the Chair 13:40 plate based screening Gene expression assay09:40 Primary cells and 3D models in Label-free as well as assayhigh-throughput screening development native neuronal cell typesRobin Ketteler MRC LMCB University Presentation from PfizerCollege London 2:00 Sponsor Speaking section contact10:20 Polarity markers as functional tareef.ahmed@atta-online.co.uk for morereadouts of hepatic toxicity in 3D detailuse of bacterial artificial chromosome toensure physiological levels of tpj1-cherry 14:20 Beta-Arrestin 2 in Drugpolarity marker expression 3 dimensional Discoverycell culture to ensure polarity and Deorphanisationfunctional bile canaliculi system HTSgeneration of transgenic animals for Biased signalingprimary cell culture high throughput Scavangerimaging of live polarised hepatocytes In-vitro to in-vivoautomated image analysis Xavier Leroy, Ph.D. Project PromoterMarc Bickle Head of Technology & Leader Associate Director DrugDevelopment Studio at Max Planck Discovery Dept. ActelionInstitute of Molecular Cell Biology and Pharmaceuticals LtdGenetics 15:00 Afternoon Refreshments11:00 Morning refreshments 15:20 Sponsor Speaking section contact tareef.ahmed@atta-online.co.uk for more11:20 Application of in vitro 3D models detailfor drug discoveryMore complex and therefore 16:00 High-Content screen forphysiologically more relevant cell-based inhibitors of cell migration in cancerassays will ultimately be more predictive metastasis using adenoviral knock-than current 2D-based assays. down, high-throughput wound healingTechnologies and assay set-up for assay which we developed to identifymedium-throughput compound screening novel genes involved in metastatic cellin 3D (co-) cultures migration. Genes whose knock-downHigh-content analysis is a versatile inhibit cell migration were identifiedtechnology platform to capture complex by their effect on the open woundcell-based assays. Remko de Pril Galapagos TeamApplications in oncology, virology and Leader Target Discovery and High-safety pharmacology Content Screening 16:40 Closing remarks from the ChairEberhard Krausz, Director, AssayDevelopment & Target Validation, 16:50 End of the conferenceEnabling Biology, Janssen Research &Development, Belgium12:00 3D Microtissues for EarlyCompound De-RiskingJens Kelm, PhD, co-founder of InSpheroAG
  5. 5. Registration Form for Cell Based Assays 2012 26th -27th June 2012, London UK.DELEGATE DETAILSPlease complete fully and clearly in capital letters and e-mail it totareef.ahmed@atta-online.co.ukPlease photocopy for additional delegates.Price: £499Title:Forename:Surname:Job Title:Department/Division:Company/Organisation:Email:Address:Town/City:Post/Zip Code: Country:Direct Tel: Direct Fax:Mobile:Switchboard:Signature:Date:I agree to be bound by ATTA’s Terms and Conditions of Booking. Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately andprior to the start of the event. If payment has not been received then credit card details will be requested and paymenttaken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the DocumentPortal will not be given until payment has been received.Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take yourplace at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please makeseparate bookings for each delegate.Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we willrefund/credit 50% of the due fee less a £50 administration charge,providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfullycancellation after this time cannot be accepted. We will however provide the conferences documentation via theDocument Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of theBriefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations oforders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have tocancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of theevent compared to the advertised programme